Source: BEFREE

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE In validation set, CEs potently distinguished PCa and non-malignance (AUC, 0.84-0.91), and discriminated PCa and benign prostatic hyperplasia (BPH) (AUC, 0.90-0.96), superior to serum prostate-specific antigen (PSA) (AUC = 0.83). 26865432

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE The expression of EP biomarkers in this cohort of men with a low risk of PC-specific mortality was not associated with aggressive features or PSA relapse after surgery. 26458958

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE However, the prostate-specific antigen screening test has proved to be a double-edged sword so far, as it also accounts for PCa overdiagnosis. 26548550

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Additionally, knockdown of PABPC1 inhibited transactivation of the PSA promoter by NAR (AR lacking the LBD) and attenuated proliferation of AR-positive prostate cancer cells. 26176602

2016

Entrez Id: 2100
Gene Symbol: ESR2
ESR2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE The estrogen receptor (ER) β variant ERβ2 is expressed in aggressive castration-resistant prostate cancer and has been shown to correlate with decreased overall survival. 26010887

2016

Entrez Id: 2100
Gene Symbol: ESR2
ESR2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE ERβ regulation of NF-kB activation in prostate cancer is mediated by HIF-1. 26450901

2016

Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. 27433846

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE Following negative initial findings of biopsy sample analysis, total serum PSA levels and serum PSA kinetics are ineffective indicators of a need for a repeat biopsy; therefore, patients suspected of having prostate cancer might undergo several unnecessary biopsy procedures. 26171803

2016

Entrez Id: 7015
Gene Symbol: TERT
TERT
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE Previous research identified four single nucleotide polymorphisms (SNPs) principally associated with circulating PSA levels rather than with prostate cancer risk (TERT rs2736098, FGFR2 rs10788160, TBX3 rs11067228, KLK3 rs17632542). 26431041

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE We investigated associations of sixteen SNPs across seven genes with prostate-specific antigen-detected prostate cancer. 25488826

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Prostate specific antigen, pathological stage, node stage and Gleason score were the only significant predictors for biochemical recurrence-free survival, while pathological stage, node stage (all p <0.005) and Gleason score (Gleason 7 vs 6 or less-HR 1.711, 95% CI 1.056-2.774, p = 0.03; Gleason 8 or greater vs 6 or less-HR 4.516, 95% CI 2.776-7.347, p <0.0001) were the only predictors for prostate cancer specific survival. 26239337

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE In men with clinically localized prostate cancer who have undergone at least 1 previous negative biopsy and have elevated serum prostate-specific antigen (PSA) levels, long-term health outcomes associated with the assessment of urinary prostate cancer antigen 3 (PCA3) and the transmembrane protease, serine 2 (TMPRSS2):v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG) gene fusion (T2:ERG) have not been investigated previously in relation to the decision to recommend a repeat biopsy. 26280815

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE There is an urgent need to develop novel biomarkers for PCa prognosis and diagnosis in the post prostate-specific antigen era. 26100580

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Therefore, we investigated the validity of CCL2 as a complementary biomarker to PSA for prostate cancer. 26701731

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE The expression of ALDH1A3 was measured in urine samples to evaluate the predictive capability of this biomarker for the presence of PCa and, at a signification level of 10%, PSA and also ALDH1A3 were significantly associated with a positive biopsy of PCa. 25969992

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE A novel molecular signature (EXO106 score) derived from non-DRE urine demonstrated independent, negative predictive value for the diagnosis of high-grade PCa from initial biopsy for men with 'gray zone' serum PSA levels. 26345389

2016

Entrez Id: 2100
Gene Symbol: ESR2
ESR2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE We identify two independent susceptibility loci for prostate cancer at 11p15.4 (rs12791447, P=3.59 × 10(-8); PPFIBP2) and 14q23.2 (rs58262369, P=6.05 × 10(-10); ESR2). 26443449

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE At the same level of sensitivity as the PSA test using a cutoff of ≥3 ng/mL to diagnose high risk prostate cancer, use of the STHLM3 model could reduce the number of biopsies by 32% (95% CI 24-39) and could avoid 44% (35-54) of benign biopsies. 26563502

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Current prostate cancer (PCa) biomarkers such as PSA are not optimal in distinguishing cancer from benign prostate diseases and predicting disease outcome. 25686826

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. 25746941

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE This is especially important because screening for prostate cancer based on prostate-specific antigen remains controversial due to the high rate of overdiagnosis and unnecessary prostate biopsies, despite evidence that it reduces mortality. 26074382

2016

Entrez Id: 2100
Gene Symbol: ESR2
ESR2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE This finding provides a mechanism for how ERβ expression is regulated in prostate cancer. 25818291

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE The established methods for detecting prostate cancer (CaP) are based on tests using PSA (blood), PCA3 (urine), and AMACR (tissue) as biomarkers in patient samples. 25889691

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE For individuals diagnosed with PCa clinicopathological characteristics including serum prostate-specific antigen level at diagnosis, Gleason score (GS), and clinical stage were determined. 25084752

2016

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). 26332304

2016